van den Eertwegh AJM - Search Results

1

Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial.

Mulder EEAP, de Joode K, Litière S, Ten Tije AJ, Suijkerbuijk KPM, Boers-Sonderen MJ, Hospers GAP, de Groot JWB, van den Eertwegh AJM, Aarts MJB, Piersma D, van Rijn RS, Kapiteijn E, Vreugdenhil G, van den Berkmortel FWPJ, Hoop EO, Franken MG, Ryll B, Rutkowski P, Sleijfer S, Haanen JBAG, van der Veldt AAM. Mulder EEAP, et al. Among authors: van den eertwegh ajm, van der veldt aam, van den berkmortel fwpj, van rijn rs. BMC Cancer. 2021 Mar 25;21(1):323. doi: 10.1186/s12885-021-08018-w. BMC Cancer. 2021. PMID: 33765967 Free PMC article.

2

Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients.

Haanen JB, Baars A, Gomez R, Weder P, Smits M, de Gruijl TD, von Blomberg BM, Bloemena E, Scheper RJ, van Ham SM, Pinedo HM, van den Eertwegh AJ. Haanen JB, et al. Cancer Immunol Immunother. 2006 Apr;55(4):451-8. doi: 10.1007/s00262-005-0018-5. Epub 2005 Jul 21. Cancer Immunol Immunother. 2006. PMID: 16034562 Free PMC article. Clinical Trial.

3

[Adverse effects of the tyrosine-kinase inhibitor sunitinib, a new drug for the treatment of advanced renal-cell cancer].

van der Veldt AA, van den Eertwegh AJ, Boven E. van der Veldt AA, et al. Ned Tijdschr Geneeskd. 2007 May 19;151(20):1142-7. Ned Tijdschr Geneeskd. 2007. PMID: 17557672 Dutch.

4

Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy.

van der Veldt AA, van den Eertwegh AJ, Hoekman K, Barkhof F, Boven E. van der Veldt AA, et al. Ann Oncol. 2007 Oct;18(10):1747-50. doi: 10.1093/annonc/mdm455. Ann Oncol. 2007. PMID: 17890217 Free article. No abstract available.

5

[Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus].

de Mulder PH, Haanen JB, Sleijfer S, Kruit WH, Gietema JA, Richel DJ, Groenewegen G, Voest EE, van den Eertwegh AJ, Osanto S, Jansen RL, Mulders PF. de Mulder PH, et al. Ned Tijdschr Geneeskd. 2008 Feb 16;152(7):371-5. Ned Tijdschr Geneeskd. 2008. PMID: 18380383 Review. Dutch.

6

Sunitinib for treatment of advanced renal cell cancer: primary tumor response.

van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Bex A, de Gast G, Haanen JB, Boven E. van der Veldt AA, et al. Clin Cancer Res. 2008 Apr 15;14(8):2431-6. doi: 10.1158/1078-0432.CCR-07-4089. Clin Cancer Res. 2008. PMID: 18413834

7

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer.

van der Veldt AA, Boven E, Helgason HH, van Wouwe M, Berkhof J, de Gast G, Mallo H, Tillier CN, van den Eertwegh AJ, Haanen JB. van der Veldt AA, et al. Br J Cancer. 2008 Jul 22;99(2):259-65. doi: 10.1038/sj.bjc.6604456. Epub 2008 Jul 1. Br J Cancer. 2008. PMID: 18594533 Free PMC article. Clinical Trial.

8

Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients.

Molenkamp BG, Sluijter BJ, van Leeuwen PA, Santegoets SJ, Meijer S, Wijnands PG, Haanen JB, van den Eertwegh AJ, Scheper RJ, de Gruijl TD. Molenkamp BG, et al. Clin Cancer Res. 2008 Jul 15;14(14):4532-42. doi: 10.1158/1078-0432.CCR-07-4711. Clin Cancer Res. 2008. PMID: 18628468 Clinical Trial.

9

Metastatic renal cell cancer in a 20-year-old pregnant woman.

van der Veldt AA, van Wouwe M, van den Eertwegh AJ, van Moorselaar RJ, van Geijn HP. van der Veldt AA, et al. Urology. 2008 Oct;72(4):775; discussion 776-7. doi: 10.1016/j.urology.2008.04.048. Epub 2008 Aug 23. Urology. 2008. PMID: 18723209

10

Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival.

van Cruijsen H, van der Veldt AA, Vroling L, Oosterhoff D, Broxterman HJ, Scheper RJ, Giaccone G, Haanen JB, van den Eertwegh AJ, Boven E, Hoekman K, de Gruijl TD. van Cruijsen H, et al. Clin Cancer Res. 2008 Sep 15;14(18):5884-92. doi: 10.1158/1078-0432.CCR-08-0656. Clin Cancer Res. 2008. PMID: 18794101

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

243 results

Search Page